Transforming Cancer Detection with GlycoCapture® Technology

The Liquid biopsy market is a rapid growing global market in disease diagnosis.

Transforming Cancer Detection with GlycoCapture® Technology

Innovating liquid biopsy with breakthrough EV-capture technology. Next-generation platform for genomic medicine.

The global liquid biopsy for early cancer detection and monitoring market size was estimated at USD 2.23 billion in 2024 and is projected to reach USD 6.20 billion by 2033, growing at a CAGR of 12.14% from 2025 to 2033. Exosome/EV’s are poised within the same high-growth markets.

Technology

1. High-mannose N-glycans (HM)-specific spin column

This product (GlycoCapture🄬 HM) is a silica monolith spin column on which a lectin (OAA) from the cyanobacterium Oscillatoria agardhii, which selectively recognizes and binds high-mannose N-glycans (HM), is immobilized at high density and in a highly oriented manner. By using the “Purification and Extraction Kit” consisting of the column and eluent, cells, extracellular vesicles (EVs), viruses and bacteria with high mannose-type Glycan structures on their surfaces can be captured and concentrated in a Glycostructure-specific manner, and their internal components (proteins, mRNAs, miRNAs, DNAs, etc.) can be solubilized and eluted from the column.

2. Potent binding capacity of immobilized ligand (OAA)

Recognition site (pink)of OAA in HM structures Biol Chem, Vol282, 11021-11029,2007）

3. Achieving high-sensitivity cancer testing

Clinical sample validation with the technology have revealed unique miRNA profiles that enable detection/diagnosis for colorectal cancer samples, compared to normal patient samples.

4. Comparison data with other commercially available kits

Achieved more efficient EV capture compared to commercial

5. Paper publications

Achieved more efficient EV capture compared to commercial

6. Inventors & International Collaboration.

The technology’s inventors and patent holders, IT LABS, Japan have established a strong technology collaboration with CLONEX (M) SDN BHD., enabling our company to be the first to import this technology in Malaysia for research, commercialization and partnership purposes.

Get A Quote